Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Myeloma Heterogeneity within Its Complex Immune Ecosystem

Jana Jakubikova, PhD, Danka Cholujova, PhD, Gabor Beke, PhD, Zachary R Hunter, PhD, Teru Hideshima, MD PhD, Merav Leiba, MD, Krzysztof Jamroziak, MD PhD, Paul G. Richardson, MD, Eftathios Kastritis, David M. Dorfman, MD PhD, Kenneth C. Anderson, MD

Blood (2019) 134 (Supplement_1): 4354.

https://doi.org/10.1182/blood-2019-132193

Published: 2019

Journal Articles

Outcome of Relapsed DLBCL Patients, Treated with Polatuzumab-BR or Polatuzumab-R: Real Life Data

Yafit Segman, MD, Elena Ribakovsky, MD, Abraham Avigdor, MD, Vladimir Vainstein, MD, Neta Goldschmidt, MD, Shimrit Ringelstein Harlev, MD, Odit Gutwein, Uri Abadi, MD, Anatoly Nemets, MD, Orit Sofer, Najib Dally, MD, Kalman Filanovsky, MD, Merav Leiba, MD, Nadav Sarid, MD, Noam Benyamini, MD, Yair Herishanu, MD, Ron Ram, MD, Chava Perry, MD PhD, Irit Avivi

Blood (2019) 134 (Supplement_1): 5321.

https://doi.org/10.1182/blood-2019-124164

Published: 2019

Journal Articles

Clinical Characteristics, Treatment Patterns and Outcomes of Solitary Plasmacytoma - a Multicenter Retrospective Cohort Study

Svetlana Trestman, MD, Chezi Ganzel, MD, Shai Levi, MSc, Moshe E. Gatt, MD, Noa Lavi, MD, Iuliana Vaxman, MDBA, Ory Rouvio, MD, Hila Magen, MD, Netanel A Horowitz, MD, Merav Leiba, MD, Tamar Tadmor, MD, Katrin Herzog Tzarfati, MD, Celia Surio, MD, Shay Yeganeh, MD, Nagib Deli, MD, Irit Avivi, MD, Cohen Yael, Dr.

Blood (2019) 134 (Supplement_1): 3180.

https://doi.org/10.1182/blood-2019-128325

Published: 2019

Journal Articles

High-Dimensional Heterogeneity of Waldenström Macroglobulinemia within Its Immune Tumor Microenvironment

Jana Jakubikova, PhD, Danka Cholujova, PhD, Gabor Beke, PhD, Zachary R Hunter, PhD, Teru Hideshima, MD PhD, Ludmila Flores, Merav Leiba, MD, Paul G. Richardson, MD, Eftathios Kastritis, David M. Dorfman, MD PhD, Steven P Treon, MD PhD FRCP, Kenneth C. Anderson, MD

Blood (2019) 134 (Supplement_1): 3975.

https://doi.org/10.1182/blood-2019-130011

Published: 2019

Journal Articles

Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients with 1 to 3 Prior Lines of Therapy: Updated Analysis of Pollux

Saad Z Usmani, MD FACP, Meletios A Dimopoulos, Andrew Belch, Darrell White, MD, Lofti Benboubker, Gordon Cook, MD PhD, Merav Leiba, MD, James Morton, MBBS, BSc(MD, FRACP, FRCPA, P. Joy Ho, Kihyun Kim, Naoki Takezako, MD PhD, Nushmia Z Khokhar, Mary Guckert, Kaida Wu, MD PhD, Xiang Qin, Tineke Casneuf, Christopher Chiu, PhD, A. Kate Sasser, Jesús San-Miguel, MD PhD

Blood (2016) 128 (22): 1151.

https://doi.org/10.1182/blood.V128.22.1151.1151

Published: 2016

Journal Articles

Population Pharmacokinetic and Exposure-Response Analyses for Daratumumab in Combination Therapies for Patients with Multiple Myeloma Who Have Received 1 or More Prior Lines of Therapy

X. Steven Xu, Sam Liao, PhD, Meletios A Dimopoulos, Pieter Sonneveld, MD PhD, P. Joy Ho, Andrew Belch, MD, Merav Leiba, MD, Marcelo Capra, MD PhD, David Gomez, MD, Eva Medvedova, MD, Shinsuke Iida, MD PhD, Chang-Ki Min, MD, Ming Qi, Jordan Schecter, Nushmia Z. Khokhar, Xiaoyu Yan, Liping Zhang, Pamela L. Clemens

Blood (2016) 128 (22): 3340.

https://doi.org/10.1182/blood.V128.22.3340.3340

Published: 2016

Journal Articles

Evaluation of the Risk of Hepatitis B Reactivation Among Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors

Ohad Benjamini, MD, Maya Zlotnick, MD, Elena Ribakovsky, MD, Meirav Kedmi, MD, Adrian Duek, MD, Drorit Merkel, MD, Merav Leiba, MD, Ivetta Danylesko, MD, Noga Shem-Tov, MD, Ronit Yerushalmi, MD, Avichai Shimoni, MD, Abraham Avigdor, MD, Arnon Nagler, Yulia Volchek, MD

Blood (2016) 128 (22): 5429.

https://doi.org/10.1182/blood.V128.22.5429.5429

Published: 2016

Journal Articles

Primary Plasma Cell Leukemia Has a Poor Prognosis Even in the Era of Novel Agents - a Multicenter Case Series

Chezi Ganzel, Ory Rouvio, MD, Hila Magen, MD, Osnat Jarchowsky, Irit Avivi, MD, Katrin Herzog, Cohen Yossi, Tamar Tadmor, MD, Netanel A Horowitz, MD, Merav Leiba, MD, Arnon Nagler, MD MSc, Yael Cohen, MD, Shlomo Bulvik, MD, Dina Ben Yehuda, MD, Jacob M. Rowe, MD, Moshe E. Gatt, MD

Blood (2016) 128 (22): 5699.

https://doi.org/10.1182/blood.V128.22.5699.5699

Published: 2016

Journal Articles

The mTOR Inhibitor Everolimus Overcomes CXCR4-Mediated Resistance to HDAC Inhibitor Panobinostat through Inhibition of p21 and Mitosis Regulators, Sensitizing MM Cells to DNA-Damaged Induced Apoptosis

Katia Beider, PhD, Valeria Voevoda, Hanna Bitner, Evgenia Rosenberg, Hila Magen, MD, Olga Ostrovsky, PhD, Merav Leiba, MD, Noya Shilo, MD, Avichai Shimoni, MD, Michael Milyavsky, PhD, Amnon Peled, PhD, Arnon Nagler

Blood (2016) 128 (22): 891.

https://doi.org/10.1182/blood.V128.22.891.891

Published: 2016

Journal Articles

Blockade of PD-1 in Combination with Dendritic Cell/Myeloma Fusion Cell Vaccination Following Autologous Stem Cell Transplantation Is Well Tolerated, Induces Anti-Tumor Immunity and May Lead to Eradication of Measureable Disease

Blood (2015) 126 (23): 4218.

https://doi.org/10.1182/blood.V126.23.4218.4218

Published: 2015

Journal Articles

STK405759 As a Novel Tubulin Active Agent for Multiple Myeloma Therapy

Gabriela Rozic, PhD, Paukov Lena, MSc, Jana Jakubikova, PhD, Duek Adrian, MD, Abraham Avigdor, MD, Arnon Nagler, MD MSc, Merav Leiba, MD

Blood (2015) 126 (23): 5348.

https://doi.org/10.1182/blood.V126.23.5348.5348

Published: 2015

Journal Articles

Evaluation of Immune Profile in Patients with Multiple Myeloma Using Cytof Technology

Jana Jakubikova, PhD, Efstathios Kastritis, MD, Danka Cholujova, PhD, Teru Hideshima, MD PhD, Ludmila M Flores, Merav Leiba, MD, Jacob P. Laubach, MD, Nikhil C. Munshi, MD, Paul Richardson, MD, David M Dorfman, MD PhD, Kenneth C. Anderson, MD PhD

Blood (2014) 124 (21): 3404.

https://doi.org/10.1182/blood.V124.21.3404.3404

Published: 2014

Journal Articles

S1P Modulator FTY720 Targets Multiple Myeloma Cell Proliferation and Stromal Interactions Via CXCR4/CXCL12 and mTOR Pathways

Katia Beider, PhD, Evgenia Rosenberg, Hanna Bitner, Merav Leiba, MD, Maya Koren-Michowitz, MD, Michal Abraham, PhD, Shiri Klein, Hanna Wald, Avichai Shimoni, MD, Amnon Peled, PhD, Arnon Nagler, MD

Blood (2014) 124 (21): 4707.

https://doi.org/10.1182/blood.V124.21.4707.4707

Published: 2014

Journal Articles

Jewish Immigrants Of Middle Eastern Origin Have a Lower Incidence Of Multiple Myeloma Compared To Both North African and European Jews In a Cohort Of 746,200 Israeli Men Followed From Late Adolescence

Merav Leiba, MD, Arnon Afek, MD, Estela Derazne, MA, Adi Leiba, MD, MHA, Lital Keinan-Boker, MD, Ari Shamiss, MD, MHA, Arnon Nagler, MD, MHA, Jeremy D. Kark, MD

Blood (2013) 122 (21): 5346.

https://doi.org/10.1182/blood.V122.21.5346.5346

Published: 2013

Journal Articles

Randomized Placebo-Controlled Phase III Study Of Perifosine Combined With Bortezomib and Dexamethasone In Relapsed, Refractory Multiple Myeloma Patients Previously Treated With Bortezomib

Blood (2013) 122 (21): 3189.

https://doi.org/10.1182/blood.v122.21.3189.3189

Published: 2013

Journal Articles

Halofuginone, a Novel Antimyeloma Agent, Upregulates C-Jun, JNK and P-53 Protein in Vitro , and Inhibits Tumor Growth and Improves Survival in in Vivo M ultiple Myeloma(MM) Animal Models

Merav Leiba, MD, Jana Jakubikova, Steffen Klippel, Constantine S. Mitsiades, MD, PhD, Teru Hideshima, Yu-Tzu Tai, Paul Richardson, Yutaka Okawa, Hiroshi Ikeda, Arnon Nagler, Kenneth C. Anderson

Blood (2008) 112 (11): 2754.

https://doi.org/10.1182/blood.V112.11.2754.2754

Published: 2008

Journal Articles

Halofuginone, an Old Anticoccidosis Drug, Induces Apoptosisin Multiple Myeloma Cells, Associated with Down Regulation of MCL1.

Merav Leiba, MD, Yu-Tzu Tai, PHD, Teru Hideshima, MD, PHD, Jana Jakubikova, PHD, Ikeda Hiroshi, MD, PHD, Xian-Feng Li, MS, Peter Burger, BS, Paul Richardson, MD, Nikhil C. Munshi, MD, Arnon Nagler, MD, Kenneth C. Anderson, MD

Blood (2007) 110 (11): 4786.

https://doi.org/10.1182/blood.V110.11.4786.4786

Published: 2007

Journal Articles

Urinary Hepcidin Excretion in Patients with Myelodysplastic Syndrome (MDS) and Myelofibrosis (MF).

Asher Winder, MD, Rafi Lefkowitz, Hussam Ghoti, MD, Merav Leiba, MD, Tomas Ganz, MD, PhD, Elizabeta Nemeth, MD, E.A. Rachmilewitz, MD

Blood (2006) 108 (11): 2620.

https://doi.org/10.1182/blood.V108.11.2620.2620

Published: 2006

Journal Articles

No Evidence for Increased Transplant Related Complications in Ph+ Chronic Myelogenous Leukemia and Acute Lymphoblastic Leukemia with Prior Treatment with Dasatinib.

Merav Leiba, MD, Avichai Shimoni, MD, Francois Guilhot, MD, Geraldine Martineau, MD, Marc Renaud, MD, Sylvie Francois, MD, Izhar Hardan, MD, Arnon Nagler, MD

Blood (2006) 108 (11): 2975.

https://doi.org/10.1182/blood.V108.11.2975.2975

Published: 2006

Journal Articles

No Evidence for Iron Overload in the Heart of Multitransfused Elderly Patients with Sideroblastic Anemia (RARS) Measured by T2* MRI.

Asher Winder, MD, Eli Konen, MD, Tammar Kushnir, PhD, Merav Leiba, MD, Eliezer Rachmilewitz, MD

Blood (2005) 106 (11): 2536.

https://doi.org/10.1182/blood.V106.11.2536.2536

Published: 2005

NARROW

Myeloma Heterogeneity within Its Complex Immune Ecosystem

Outcome of Relapsed DLBCL Patients, Treated with Polatuzumab-BR or Polatuzumab-R: Real Life Data

Clinical Characteristics, Treatment Patterns and Outcomes of Solitary Plasmacytoma - a Multicenter Retrospective Cohort Study

High-Dimensional Heterogeneity of Waldenström Macroglobulinemia within Its Immune Tumor Microenvironment

Efficacy of Daratumumab, Lenalidomide, and Dexamethasone Versus Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients with 1 to 3 Prior Lines of Therapy: Updated Analysis of Pollux

Population Pharmacokinetic and Exposure-Response Analyses for Daratumumab in Combination Therapies for Patients with Multiple Myeloma Who Have Received 1 or More Prior Lines of Therapy

Evaluation of the Risk of Hepatitis B Reactivation Among Patients with Chronic Myeloid Leukemia Treated with Tyrosine Kinase Inhibitors

Primary Plasma Cell Leukemia Has a Poor Prognosis Even in the Era of Novel Agents - a Multicenter Case Series

The mTOR Inhibitor Everolimus Overcomes CXCR4-Mediated Resistance to HDAC Inhibitor Panobinostat through Inhibition of p21 and Mitosis Regulators, Sensitizing MM Cells to DNA-Damaged Induced Apoptosis

Blockade of PD-1 in Combination with Dendritic Cell/Myeloma Fusion Cell Vaccination Following Autologous Stem Cell Transplantation Is Well Tolerated, Induces Anti-Tumor Immunity and May Lead to Eradication of Measureable Disease

STK405759 As a Novel Tubulin Active Agent for Multiple Myeloma Therapy

Evaluation of Immune Profile in Patients with Multiple Myeloma Using Cytof Technology

S1P Modulator FTY720 Targets Multiple Myeloma Cell Proliferation and Stromal Interactions Via CXCR4/CXCL12 and mTOR Pathways

Jewish Immigrants Of Middle Eastern Origin Have a Lower Incidence Of Multiple Myeloma Compared To Both North African and European Jews In a Cohort Of 746,200 Israeli Men Followed From Late Adolescence

Randomized Placebo-Controlled Phase III Study Of Perifosine Combined With Bortezomib and Dexamethasone In Relapsed, Refractory Multiple Myeloma Patients Previously Treated With Bortezomib

Halofuginone, a Novel Antimyeloma Agent, Upregulates C-Jun, JNK and P-53 Protein in Vitro , and Inhibits Tumor Growth and Improves Survival in in Vivo M ultiple Myeloma(MM) Animal Models

Halofuginone, an Old Anticoccidosis Drug, Induces Apoptosisin Multiple Myeloma Cells, Associated with Down Regulation of MCL1.

Urinary Hepcidin Excretion in Patients with Myelodysplastic Syndrome (MDS) and Myelofibrosis (MF).

No Evidence for Increased Transplant Related Complications in Ph+ Chronic Myelogenous Leukemia and Acute Lymphoblastic Leukemia with Prior Treatment with Dasatinib.

No Evidence for Iron Overload in the Heart of Multitransfused Elderly Patients with Sideroblastic Anemia (RARS) Measured by T2* MRI.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only